<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011420'>Death</z:hpo>-associated protein kinase (DAP-kinase), a proapoptotic serine/threonine kinase, is a candidate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the methylation status of DAP-kinase of 194 bone marrow samples from 160 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and 34 with a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) at the time of initial diagnosis by polymerase chain reaction (PCR) </plain></SENT>
<SENT sid="2" pm="."><plain>Hypermethylation of DAP-kinase was present in 27.5% (44 of 160) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and in 47% (16 of 34) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> specimens and significantly correlated to loss of DAP-kinase expression (P =.008) </plain></SENT>
<SENT sid="3" pm="."><plain>It was significantly more frequent in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> secondary to therapy for other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; 14 of 29, 48.3%), as compared to de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (30 of 131, 22.9%, P =.01) </plain></SENT>
<SENT sid="4" pm="."><plain>DAP-kinase hypermethylation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was associated with myelodysplastic changes in the bone marrow at the time of the initial diagnosis (P =.002) and with the presence of cytogenetic abnormalities (P =.02) </plain></SENT>
<SENT sid="5" pm="."><plain>Alteration in the apoptotic response due to the loss of DAP-kinase function may be an early event in the transformation pathway to secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> via <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> </plain></SENT>
</text></document>